{"gene":"MAPK8IP2","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2024,"finding":"JIP2 (MAPK8IP2) homodimerizes via its SH3 domain, and heterodimerizes with JIP1 via their SH3 domains with comparable affinity. Crystal structure of the JIP2-SH3 homodimer revealed charge differences at the dimer interface that form compensatory hydrogen bonds and salt bridges distinguishing it from JIP1-SH3. Targeted mutations in cellulo demonstrated a functional role for JIP1/JIP2 dimerization in activation of the JNK signaling pathway.","method":"NMR, X-ray crystallography, site-directed mutagenesis, cell-based JNK activation assays","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus NMR plus mutagenesis with functional validation in a single rigorous study","pmids":["39013462"],"is_preprint":false},{"year":2018,"finding":"Loss of JIP2 (MAPK8IP2) in human pluripotent stem cell-derived neural progenitor cells leads to simultaneous down-regulation of JNK proteins and impaired generation of mature neurons, placing JIP2 upstream of JNK activity in neuronal maturation. Pharmacological activation of neuropilin receptor 1 (NRP1) rescued impaired semaphorin pathway activity and JNK expression in patient neurons, suggesting JIP2/JNK complex involvement in semaphorin signaling.","method":"iPSC genome editing (haploinsufficiency), neural differentiation assays, western blotting for JNK, pharmacological rescue with NRP1 agonist","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO/haploinsufficiency in human iPSC-derived neurons with defined cellular phenotype and pharmacological rescue, single lab","pmids":["30456368"],"is_preprint":false},{"year":2019,"finding":"HPV E6 oncoprotein selectively upregulates translation of JIP2 (MAPK8IP2) mRNA (along with WNT4 and JIP1), activating the noncanonical WNT/PCP/JNK pathway to promote cell proliferation. Ectopic expression of WNT4/JIP2 rescued decreased cell proliferation caused by E6 silencing, establishing JIP2 as a downstream effector of E6 in cervical cancer cell proliferation.","method":"Polysome profiling, deep RNA sequencing, siRNA silencing, ectopic overexpression rescue assays, in vitro and in vivo tumor growth assays","journal":"Signal transduction and targeted therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (polysome profiling, silencing, rescue) in single lab establishing translational regulation and pathway placement","pmids":["31637011"],"is_preprint":false},{"year":2019,"finding":"In IB2 (MAPK8IP2) knockout mice, cerebellar granule cells show larger NMDA receptor-mediated currents and enhanced intrinsic excitability, raising the excitatory/inhibitory balance. Loss of IB2/MAPK8IP2 also increases the size and extension of long-term synaptic plasticity and alters spatial organization of granular layer responses from a 'Mexican hat' to a 'stovepipe hat' profile, disrupting signal transfer.","method":"Whole-cell patch-clamp electrophysiology, field potential recordings, long-term plasticity assays in IB2 KO mouse cerebellar slices","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO mouse with multiple electrophysiological readouts (NMDA currents, intrinsic excitability, LTP) establishing mechanistic role in cerebellar granule cell signaling","pmids":["30696733"],"is_preprint":false},{"year":2022,"finding":"CTRP3 physically interacts with LAMP1 and JIP2 (MAPK8IP2) as shown by Co-IP. LAMP1 silencing aggravates inhibition of JIP2 and JNK protein expression during ischemia/reperfusion, while LAMP1 overexpression restores JIP2/JNK levels. JNK inhibitor SP600125 reverses cardioprotective effects of CTRP3 overexpression, establishing a CTRP3–LAMP1–JIP2–JNK axis in myocardial I/R injury.","method":"Co-immunoprecipitation, siRNA knockdown, overexpression, western blotting, JNK inhibitor (SP600125) treatment, in vivo mouse I/R model","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP identifying physical complex, confirmed in two papers from same group with consistent results across in vitro and in vivo models","pmids":["35278832","35114641"],"is_preprint":false},{"year":2018,"finding":"In Theileria annulata-infected macrophages, infection-induced upregulation of miR-126-5p ablates JIP-2 (MAPK8IP2) expression, releasing cytosolic JNK1 to translocate to the nucleus and trans-activate AP-1-driven transcription of MMP9. In attenuated macrophages, lower miR-126-5p levels allow JIP-2 to accumulate, retaining JNK1 in the cytosol and dampening c-Jun phosphorylation and MMP9 transcription.","method":"Deep RNAseq, miRNA manipulation, western blotting for JIP-2 and JNK1 localization, luciferase reporter assays, AGO2 phosphorylation analysis","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods establishing miR-126-5p → JIP-2 → JNK cytosolic retention axis, single lab but well-supported mechanistically","pmids":["29570727"],"is_preprint":false}],"current_model":"MAPK8IP2 (JIP2/IB2) is a scaffold protein that organizes the JNK signaling pathway: it homodimerizes and heterodimerizes with JIP1 via SH3 domains (crystal structure resolved), and these dimers are required for JNK pathway activation; in neurons JIP2 supports JNK expression and activity required for neuronal maturation; in non-neuronal contexts JIP2 retains JNK in the cytosol to suppress AP-1-driven transcription, a function overridden by miR-126-5p-mediated JIP2 suppression; JIP2 also participates in a cardioprotective CTRP3–LAMP1–JIP2–JNK axis during ischemia/reperfusion injury; and in cervical cancer cells HPV E6 drives selective JIP2 translation to activate noncanonical WNT/PCP/JNK signaling and cell proliferation."},"narrative":{"mechanistic_narrative":"MAPK8IP2 (JIP2/IB2) is a cytoplasmic scaffold protein that organizes the JNK signaling cascade and governs whether JNK activity is restrained in the cytosol or licensed to drive downstream transcription [PMID:39013462, PMID:29570727]. It homodimerizes through its SH3 domain and heterodimerizes with JIP1 through their SH3 domains with comparable affinity; the JIP2-SH3 homodimer crystal structure reveals interface charge differences forming compensatory hydrogen bonds and salt bridges, and disrupting these dimer contacts impairs activation of the JNK pathway, establishing dimerization as a requirement for pathway output [PMID:39013462]. In neurons, JIP2 acts upstream of JNK to sustain JNK protein levels and is required for the generation of mature neurons, with its loss linked to defective semaphorin/NRP1 signaling [PMID:30456368], while in cerebellar granule cells JIP2 loss raises NMDA receptor-mediated currents, intrinsic excitability, and long-term plasticity, distorting spatial signal transfer in the granular layer [PMID:30696733]. In non-neuronal settings JIP2 retains JNK1 in the cytosol to suppress AP-1/c-Jun-driven MMP9 transcription, a brake that is released when miR-126-5p ablates JIP2 expression [PMID:29570727]. JIP2 is also recruited into a CTRP3–LAMP1–JIP2–JNK axis that confers cardioprotection during myocardial ischemia/reperfusion [PMID:35278832, PMID:35114641], and its translation is selectively upregulated by HPV E6 to activate noncanonical WNT/PCP/JNK signaling and promote cervical cancer cell proliferation [PMID:31637011].","teleology":[{"year":2018,"claim":"Established JIP2 as a determinant of JNK subcellular localization, answering whether JIP2 acts by spatially controlling JNK rather than merely binding it.","evidence":"RNAseq, miRNA manipulation, and JNK1 localization analysis in Theileria-infected macrophages","pmids":["29570727"],"confidence":"Medium","gaps":["Direct demonstration that JIP2 physically tethers JNK1 in the cytosol not shown","Generality beyond the infection context untested"]},{"year":2018,"claim":"Placed JIP2 upstream of JNK in human neuronal maturation, addressing whether JIP2 controls JNK abundance during neural differentiation.","evidence":"iPSC genome editing haploinsufficiency, neural differentiation, JNK western blotting, NRP1 agonist rescue","pmids":["30456368"],"confidence":"Medium","gaps":["Mechanism by which JIP2 loss lowers JNK protein levels unresolved","Direct biochemical link between JIP2 and semaphorin/NRP1 signaling not shown"]},{"year":2019,"claim":"Defined a physiological neuronal consequence of JIP2 loss, showing it shapes cerebellar granule cell excitability and plasticity rather than acting only in development.","evidence":"Whole-cell patch-clamp, field potential recordings, and LTP assays in IB2 knockout mouse cerebellar slices","pmids":["30696733"],"confidence":"High","gaps":["Molecular link between JIP2 scaffolding and NMDA receptor current changes not established","Whether the phenotype is JNK-dependent untested"]},{"year":2019,"claim":"Identified JIP2 as a translationally regulated effector downstream of HPV E6, answering how E6 engages noncanonical WNT/JNK signaling to drive proliferation.","evidence":"Polysome profiling, RNAseq, siRNA silencing, ectopic rescue, in vitro and in vivo tumor growth assays","pmids":["31637011"],"confidence":"Medium","gaps":["Mechanism of selective JIP2 mRNA translation by E6 not defined","Direct scaffolding role of JIP2 in WNT/PCP/JNK output not biochemically dissected"]},{"year":2022,"claim":"Embedded JIP2 in a cardioprotective signaling axis, showing it physically associates with CTRP3 and LAMP1 to modulate JNK during I/R injury.","evidence":"Co-immunoprecipitation, siRNA knockdown, overexpression, JNK inhibitor treatment, in vivo mouse I/R model","pmids":["35278832","35114641"],"confidence":"Medium","gaps":["Co-IP without reciprocal or structural validation of the JIP2–LAMP1 interaction","Direct vs indirect nature of CTRP3–JIP2 contact unresolved"]},{"year":2024,"claim":"Provided the structural and functional basis for JIP2 dimerization, resolving how SH3-mediated homo- and heterodimers control JNK pathway activation.","evidence":"NMR, X-ray crystallography of the JIP2-SH3 homodimer, site-directed mutagenesis, cell-based JNK activation assays","pmids":["39013462"],"confidence":"High","gaps":["Stoichiometry and architecture of full-length JIP1/JIP2 scaffolds with kinases not resolved","How dimerization couples to specific JNK substrate selection unknown"]},{"year":null,"claim":"How JIP2 scaffolding switches between cytosolic JNK retention and active JNK pathway assembly across cell types remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking SH3 dimerization state to JNK localization","Full set of kinase partners assembled on the JIP2 scaffold not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,5]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,4,5]}],"complexes":[],"partners":["MAPK8IP1","LAMP1","CTRP3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13387","full_name":"C-Jun-amino-terminal kinase-interacting protein 2","aliases":["Islet-brain-2","IB-2","JNK MAP kinase scaffold protein 2","Mitogen-activated protein kinase 8-interacting protein 2"],"length_aa":824,"mass_kda":88.0,"function":"The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module. JIP2 inhibits IL1 beta-induced apoptosis in insulin-secreting cells. May function as a regulator of vesicle transport, through interactions with the JNK-signaling components and motor proteins (By similarity)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q13387/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MAPK8IP2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":77,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MAPK8IP2","total_profiled":1310},"omim":[{"mim_id":"608682","title":"ADRENOMEDULLIN 2; ADM2","url":"https://www.omim.org/entry/608682"},{"mim_id":"607755","title":"MITOGEN-ACTIVATED PROTEIN KINASE 8-INTERACTING PROTEIN 2; MAPK8IP2","url":"https://www.omim.org/entry/607755"},{"mim_id":"606232","title":"PHELAN-MCDERMID SYNDROME; PHMDS","url":"https://www.omim.org/entry/606232"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":103.2}],"url":"https://www.proteinatlas.org/search/MAPK8IP2"},"hgnc":{"alias_symbol":["IB2","JIP2"],"prev_symbol":["PRKM8IPL"]},"alphafold":{"accession":"Q13387","domains":[{"cath_id":"2.30.30.40","chopping":"595-668","consensus_level":"medium","plddt":86.6674,"start":595,"end":668},{"cath_id":"2.30.29.30","chopping":"679-819","consensus_level":"medium","plddt":83.8109,"start":679,"end":819}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13387","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13387-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13387-F1-predicted_aligned_error_v6.png","plddt_mean":51.34},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MAPK8IP2","jax_strain_url":"https://www.jax.org/strain/search?query=MAPK8IP2"},"sequence":{"accession":"Q13387","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13387.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13387/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13387"}},"corpus_meta":[{"pmid":"23640393","id":"PMC_23640393","title":"Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102).","date":"2013","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23640393","citation_count":102,"is_preprint":false},{"pmid":"37656948","id":"PMC_37656948","title":"Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994.","date":"2023","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37656948","citation_count":96,"is_preprint":false},{"pmid":"24395863","id":"PMC_24395863","title":"Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.","date":"2014","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24395863","citation_count":92,"is_preprint":false},{"pmid":"15047221","id":"PMC_15047221","title":"Detection of pelvic lymph node micrometastasis in stage IA2-IB2 cervical cancer by immunohistochemical analysis.","date":"2004","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15047221","citation_count":73,"is_preprint":false},{"pmid":"9015301","id":"PMC_9015301","title":"A heterodimer of thioredoxin and I(B)2 cooperates with Sec18p (NSF) to promote yeast vacuole inheritance.","date":"1997","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9015301","citation_count":61,"is_preprint":false},{"pmid":"25078340","id":"PMC_25078340","title":"Surgical principles for managing stage IB2, IIA2, and IIB uterine cervical cancer (Bulky Tumors) in Japan: a survey of the Japanese Gynecologic Oncology Group.","date":"2014","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/25078340","citation_count":46,"is_preprint":false},{"pmid":"9159350","id":"PMC_9159350","title":"Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix.","date":"1997","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/9159350","citation_count":39,"is_preprint":false},{"pmid":"24919188","id":"PMC_24919188","title":"Responses of a triple mutant defective in three iron deficiency-induced Basic Helix-Loop-Helix genes of the subgroup Ib(2) to iron deficiency and salicylic acid.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24919188","citation_count":33,"is_preprint":false},{"pmid":"17713822","id":"PMC_17713822","title":"Para-aortic involvement and interest of para-aortic lymphadenectomy after chemoradiation therapy in patients with stage IB2 and II cervical carcinoma radiologically confined to the pelvic cavity.","date":"2007","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17713822","citation_count":32,"is_preprint":false},{"pmid":"22614251","id":"PMC_22614251","title":"Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).","date":"2012","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/22614251","citation_count":31,"is_preprint":false},{"pmid":"15863134","id":"PMC_15863134","title":"Management strategies for stage IB2 cervical cancer: a cost-effectiveness analysis.","date":"2005","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15863134","citation_count":31,"is_preprint":false},{"pmid":"30696733","id":"PMC_30696733","title":"Hyperexcitability and Hyperplasticity Disrupt Cerebellar Signal Transfer in the IB2 KO Mouse Model of Autism.","date":"2019","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30696733","citation_count":29,"is_preprint":false},{"pmid":"23263187","id":"PMC_23263187","title":"Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix.","date":"2012","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23263187","citation_count":24,"is_preprint":false},{"pmid":"25105092","id":"PMC_25105092","title":"Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2-IIIB Cervical Cancer.","date":"2014","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25105092","citation_count":24,"is_preprint":false},{"pmid":"35570842","id":"PMC_35570842","title":"Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB.","date":"2022","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/35570842","citation_count":22,"is_preprint":false},{"pmid":"29570727","id":"PMC_29570727","title":"miR-126-5p by direct targeting of JNK-interacting protein-2 (JIP-2) plays a key role in Theileria-infected macrophage virulence.","date":"2018","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/29570727","citation_count":22,"is_preprint":false},{"pmid":"31637011","id":"PMC_31637011","title":"E6-induced selective translation of WNT4 and JIP2 promotes the progression of cervical cancer via a noncanonical WNT signaling pathway.","date":"2019","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31637011","citation_count":20,"is_preprint":false},{"pmid":"8789003","id":"PMC_8789003","title":"Genetic diversity of Neisseria gonorrhoeae IB-2 and IB-6 isolates revealed by whole-cell repetitive element sequence-based PCR.","date":"1996","source":"Journal of clinical microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/8789003","citation_count":20,"is_preprint":false},{"pmid":"15863162","id":"PMC_15863162","title":"Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2.","date":"2005","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15863162","citation_count":18,"is_preprint":false},{"pmid":"27380169","id":"PMC_27380169","title":"Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.","date":"2016","source":"International journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27380169","citation_count":18,"is_preprint":false},{"pmid":"7635488","id":"PMC_7635488","title":"Resolution of clonal subgroups among Neisseria gonorrhoeae IB-2 and IB-6 serovars by pulsed-field gel electrophoresis.","date":"1995","source":"Genitourinary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7635488","citation_count":16,"is_preprint":false},{"pmid":"17511965","id":"PMC_17511965","title":"The C-terminal domain of the nuclear factor I-B2 isoform is glycosylated and transactivates the WAP gene in the JEG-3 cells.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17511965","citation_count":15,"is_preprint":false},{"pmid":"29429800","id":"PMC_29429800","title":"Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery +/- neoadjuvant chemotherapy.","date":"2018","source":"Journal of the Formosan Medical Association = Taiwan yi zhi","url":"https://pubmed.ncbi.nlm.nih.gov/29429800","citation_count":15,"is_preprint":false},{"pmid":"23592280","id":"PMC_23592280","title":"Outcome of stage IB2-IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy.","date":"2013","source":"International journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23592280","citation_count":15,"is_preprint":false},{"pmid":"30017539","id":"PMC_30017539","title":"Isolated para-aortic lymph node metastasis in FIGO stage IA2-IB2 carcinoma of the cervix: Revisiting the role of surgical assessment.","date":"2018","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30017539","citation_count":13,"is_preprint":false},{"pmid":"35278832","id":"PMC_35278832","title":"CTRP3 alleviates myocardial ischemia/reperfusion injury in mice through activating LAMP1/JIP2/JNK pathway.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35278832","citation_count":12,"is_preprint":false},{"pmid":"35114641","id":"PMC_35114641","title":"CTRP3 alleviates cardiac ischemia/reperfusion injury via LAMP1/JIP2/JNK signaling pathway.","date":"2022","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/35114641","citation_count":9,"is_preprint":false},{"pmid":"38097567","id":"PMC_38097567","title":"A novel circular RNA, circMAML3, promotes tumor progression of prostate cancer by regulating miR-665/MAPK8IP2 axis.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38097567","citation_count":8,"is_preprint":false},{"pmid":"23635676","id":"PMC_23635676","title":"Primary surgical management with tailored adjuvant radiation for stage IB2 cervical cancer.","date":"2013","source":"Obstetrics and gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/23635676","citation_count":8,"is_preprint":false},{"pmid":"19091305","id":"PMC_19091305","title":"Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinoma.","date":"2008","source":"American journal of obstetrics and gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/19091305","citation_count":8,"is_preprint":false},{"pmid":"29691415","id":"PMC_29691415","title":"Adjuvant chemotherapy after surgery can improve clinical outcomes for patients with IB2-IIB cervical cancer with neoadjuvant chemotherapy followed by radical surgery.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29691415","citation_count":8,"is_preprint":false},{"pmid":"30456368","id":"PMC_30456368","title":"JIP2 haploinsufficiency contributes to neurodevelopmental abnormalities in human pluripotent stem cell-derived neural progenitors and cortical neurons.","date":"2018","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/30456368","citation_count":7,"is_preprint":false},{"pmid":"34253208","id":"PMC_34253208","title":"Neoadjuvant chemotherapy combined with radical surgery for stage IB2/IIA2 cervical squamous cell carcinoma: a prospective, randomized controlled study of 35 patients.","date":"2021","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34253208","citation_count":6,"is_preprint":false},{"pmid":"33976627","id":"PMC_33976627","title":"The Multi-Course Approach of Photodynamic Therapy to Treat Invasive Cervical Cancer IB2: A Case Report.","date":"2021","source":"Case reports in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33976627","citation_count":5,"is_preprint":false},{"pmid":"39013462","id":"PMC_39013462","title":"Structural basis of homodimerization of the JNK scaffold protein JIP2 and its heterodimerization with JIP1.","date":"2024","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/39013462","citation_count":4,"is_preprint":false},{"pmid":"25350466","id":"PMC_25350466","title":"Phase I Dose-Escalation Study of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in Stages IB2 and IIA2 Cervical Cancer.","date":"2017","source":"American journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25350466","citation_count":4,"is_preprint":false},{"pmid":"34106355","id":"PMC_34106355","title":"Clinico-pathological characteristics of patients with stage IB1-IB2 (FIGO 2018) uterine cervical cancer: a nationwide study in Japan.","date":"2021","source":"International journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34106355","citation_count":4,"is_preprint":false},{"pmid":"34930255","id":"PMC_34930255","title":"Platelet-activating factor acetyl hydrolase IB2 dysregulated cell proliferation in ovarian cancer.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34930255","citation_count":3,"is_preprint":false},{"pmid":"38909186","id":"PMC_38909186","title":"The role of neoadjuvant chemotherapy before radical surgery in stage IB2/IIA2 squamous cell cervical cancers.","date":"2024","source":"BMC women's health","url":"https://pubmed.ncbi.nlm.nih.gov/38909186","citation_count":3,"is_preprint":false},{"pmid":"24551779","id":"PMC_24551779","title":"Evaluation of PKM2 and MAPK8IP2 Polymorphism in Ameloblastic Carcinoma: A Retrospective Quantitative Study.","date":"2012","source":"International journal of molecular and cellular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24551779","citation_count":2,"is_preprint":false},{"pmid":"34528406","id":"PMC_34528406","title":"Successful pregnancy with stage IB2 uterine cervical cancer: A case report.","date":"2021","source":"Cancer reports (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/34528406","citation_count":2,"is_preprint":false},{"pmid":"24406134","id":"PMC_24406134","title":"[Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].","date":"2013","source":"Zhonghua fu chan ke za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/24406134","citation_count":2,"is_preprint":false},{"pmid":"17436403","id":"PMC_17436403","title":"Histopathological findings in postoperative specimens in cervical cancer patients with stages IB2-IVA after neoadjuvant chemotherapy and preoperative plus postoperative radiotherapy.","date":"2007","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17436403","citation_count":2,"is_preprint":false},{"pmid":"17357191","id":"PMC_17357191","title":"Stage IB2 cervical cancer: brachytherapy followed by radical hysterectomy.","date":"2005","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17357191","citation_count":2,"is_preprint":false},{"pmid":"40337601","id":"PMC_40337601","title":"Intermediate‑risk factors affecting oncological outcome in patients with FIGO 2018 stage IB2 cervical cancer who do not receive adjuvant therapy.","date":"2025","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/40337601","citation_count":1,"is_preprint":false},{"pmid":"21575388","id":"PMC_21575388","title":"[Histological evaluation of cervical carcinomas in FIGO stage Ib2/IIa after neoadjuvant chemotherapy].","date":"2011","source":"Zhonghua bing li xue za zhi = Chinese journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21575388","citation_count":1,"is_preprint":false},{"pmid":"41774953","id":"PMC_41774953","title":"Pre-operative imaging in clinical International Federation of Gynecology and Obstetrics stage IB2 or less cervical carcinoma.","date":"2026","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/41774953","citation_count":0,"is_preprint":false},{"pmid":"15341256","id":"PMC_15341256","title":"[Flow cytometric DNA analysis and neoadjuvant chemotherapy of cervix cancer (stage IB2-IIIB)].","date":"2004","source":"Akusherstvo i ginekologiia","url":"https://pubmed.ncbi.nlm.nih.gov/15341256","citation_count":0,"is_preprint":false},{"pmid":"17469459","id":"PMC_17469459","title":"[Histopathological findings in postoperative specimens in cervical cancer patients (IB2-IVA) after neoadjuvant chemotherapy and preoperative radiotherapy].","date":"2007","source":"Akusherstvo i ginekologiia","url":"https://pubmed.ncbi.nlm.nih.gov/17469459","citation_count":0,"is_preprint":false},{"pmid":"11776803","id":"PMC_11776803","title":"[A clinical retrospective review of stage IB1 and IB2 cervical cancer].","date":"1999","source":"Zhonghua zhong liu za zhi [Chinese journal of oncology]","url":"https://pubmed.ncbi.nlm.nih.gov/11776803","citation_count":0,"is_preprint":false},{"pmid":"41582028","id":"PMC_41582028","title":"Neoadjuvant chemotherapy plus cadonilimab followed by extra-fascial hysterectomy for International Federation of Gynecology and Obstetrics stage IB2 cervical cancer: a prospective, multi-center, single-arm, phase 2 trial.","date":"2026","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/41582028","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":31532,"output_tokens":1958,"usd":0.061983,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8870,"output_tokens":2338,"usd":0.0514,"stage2_stop_reason":"end_turn"},"total_usd":0.113383,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2024,\n      \"finding\": \"JIP2 (MAPK8IP2) homodimerizes via its SH3 domain, and heterodimerizes with JIP1 via their SH3 domains with comparable affinity. Crystal structure of the JIP2-SH3 homodimer revealed charge differences at the dimer interface that form compensatory hydrogen bonds and salt bridges distinguishing it from JIP1-SH3. Targeted mutations in cellulo demonstrated a functional role for JIP1/JIP2 dimerization in activation of the JNK signaling pathway.\",\n      \"method\": \"NMR, X-ray crystallography, site-directed mutagenesis, cell-based JNK activation assays\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus NMR plus mutagenesis with functional validation in a single rigorous study\",\n      \"pmids\": [\"39013462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Loss of JIP2 (MAPK8IP2) in human pluripotent stem cell-derived neural progenitor cells leads to simultaneous down-regulation of JNK proteins and impaired generation of mature neurons, placing JIP2 upstream of JNK activity in neuronal maturation. Pharmacological activation of neuropilin receptor 1 (NRP1) rescued impaired semaphorin pathway activity and JNK expression in patient neurons, suggesting JIP2/JNK complex involvement in semaphorin signaling.\",\n      \"method\": \"iPSC genome editing (haploinsufficiency), neural differentiation assays, western blotting for JNK, pharmacological rescue with NRP1 agonist\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO/haploinsufficiency in human iPSC-derived neurons with defined cellular phenotype and pharmacological rescue, single lab\",\n      \"pmids\": [\"30456368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HPV E6 oncoprotein selectively upregulates translation of JIP2 (MAPK8IP2) mRNA (along with WNT4 and JIP1), activating the noncanonical WNT/PCP/JNK pathway to promote cell proliferation. Ectopic expression of WNT4/JIP2 rescued decreased cell proliferation caused by E6 silencing, establishing JIP2 as a downstream effector of E6 in cervical cancer cell proliferation.\",\n      \"method\": \"Polysome profiling, deep RNA sequencing, siRNA silencing, ectopic overexpression rescue assays, in vitro and in vivo tumor growth assays\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (polysome profiling, silencing, rescue) in single lab establishing translational regulation and pathway placement\",\n      \"pmids\": [\"31637011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In IB2 (MAPK8IP2) knockout mice, cerebellar granule cells show larger NMDA receptor-mediated currents and enhanced intrinsic excitability, raising the excitatory/inhibitory balance. Loss of IB2/MAPK8IP2 also increases the size and extension of long-term synaptic plasticity and alters spatial organization of granular layer responses from a 'Mexican hat' to a 'stovepipe hat' profile, disrupting signal transfer.\",\n      \"method\": \"Whole-cell patch-clamp electrophysiology, field potential recordings, long-term plasticity assays in IB2 KO mouse cerebellar slices\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO mouse with multiple electrophysiological readouts (NMDA currents, intrinsic excitability, LTP) establishing mechanistic role in cerebellar granule cell signaling\",\n      \"pmids\": [\"30696733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CTRP3 physically interacts with LAMP1 and JIP2 (MAPK8IP2) as shown by Co-IP. LAMP1 silencing aggravates inhibition of JIP2 and JNK protein expression during ischemia/reperfusion, while LAMP1 overexpression restores JIP2/JNK levels. JNK inhibitor SP600125 reverses cardioprotective effects of CTRP3 overexpression, establishing a CTRP3–LAMP1–JIP2–JNK axis in myocardial I/R injury.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, overexpression, western blotting, JNK inhibitor (SP600125) treatment, in vivo mouse I/R model\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP identifying physical complex, confirmed in two papers from same group with consistent results across in vitro and in vivo models\",\n      \"pmids\": [\"35278832\", \"35114641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In Theileria annulata-infected macrophages, infection-induced upregulation of miR-126-5p ablates JIP-2 (MAPK8IP2) expression, releasing cytosolic JNK1 to translocate to the nucleus and trans-activate AP-1-driven transcription of MMP9. In attenuated macrophages, lower miR-126-5p levels allow JIP-2 to accumulate, retaining JNK1 in the cytosol and dampening c-Jun phosphorylation and MMP9 transcription.\",\n      \"method\": \"Deep RNAseq, miRNA manipulation, western blotting for JIP-2 and JNK1 localization, luciferase reporter assays, AGO2 phosphorylation analysis\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods establishing miR-126-5p → JIP-2 → JNK cytosolic retention axis, single lab but well-supported mechanistically\",\n      \"pmids\": [\"29570727\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MAPK8IP2 (JIP2/IB2) is a scaffold protein that organizes the JNK signaling pathway: it homodimerizes and heterodimerizes with JIP1 via SH3 domains (crystal structure resolved), and these dimers are required for JNK pathway activation; in neurons JIP2 supports JNK expression and activity required for neuronal maturation; in non-neuronal contexts JIP2 retains JNK in the cytosol to suppress AP-1-driven transcription, a function overridden by miR-126-5p-mediated JIP2 suppression; JIP2 also participates in a cardioprotective CTRP3–LAMP1–JIP2–JNK axis during ischemia/reperfusion injury; and in cervical cancer cells HPV E6 drives selective JIP2 translation to activate noncanonical WNT/PCP/JNK signaling and cell proliferation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MAPK8IP2 (JIP2/IB2) is a cytoplasmic scaffold protein that organizes the JNK signaling cascade and governs whether JNK activity is restrained in the cytosol or licensed to drive downstream transcription [#0, #5]. It homodimerizes through its SH3 domain and heterodimerizes with JIP1 through their SH3 domains with comparable affinity; the JIP2-SH3 homodimer crystal structure reveals interface charge differences forming compensatory hydrogen bonds and salt bridges, and disrupting these dimer contacts impairs activation of the JNK pathway, establishing dimerization as a requirement for pathway output [#0]. In neurons, JIP2 acts upstream of JNK to sustain JNK protein levels and is required for the generation of mature neurons, with its loss linked to defective semaphorin/NRP1 signaling [#1], while in cerebellar granule cells JIP2 loss raises NMDA receptor-mediated currents, intrinsic excitability, and long-term plasticity, distorting spatial signal transfer in the granular layer [#3]. In non-neuronal settings JIP2 retains JNK1 in the cytosol to suppress AP-1/c-Jun-driven MMP9 transcription, a brake that is released when miR-126-5p ablates JIP2 expression [#5]. JIP2 is also recruited into a CTRP3–LAMP1–JIP2–JNK axis that confers cardioprotection during myocardial ischemia/reperfusion [#4], and its translation is selectively upregulated by HPV E6 to activate noncanonical WNT/PCP/JNK signaling and promote cervical cancer cell proliferation [#2].\",\n  \"teleology\": [\n    {\n      \"year\": 2018,\n      \"claim\": \"Established JIP2 as a determinant of JNK subcellular localization, answering whether JIP2 acts by spatially controlling JNK rather than merely binding it.\",\n      \"evidence\": \"RNAseq, miRNA manipulation, and JNK1 localization analysis in Theileria-infected macrophages\",\n      \"pmids\": [\"29570727\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct demonstration that JIP2 physically tethers JNK1 in the cytosol not shown\", \"Generality beyond the infection context untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed JIP2 upstream of JNK in human neuronal maturation, addressing whether JIP2 controls JNK abundance during neural differentiation.\",\n      \"evidence\": \"iPSC genome editing haploinsufficiency, neural differentiation, JNK western blotting, NRP1 agonist rescue\",\n      \"pmids\": [\"30456368\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which JIP2 loss lowers JNK protein levels unresolved\", \"Direct biochemical link between JIP2 and semaphorin/NRP1 signaling not shown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a physiological neuronal consequence of JIP2 loss, showing it shapes cerebellar granule cell excitability and plasticity rather than acting only in development.\",\n      \"evidence\": \"Whole-cell patch-clamp, field potential recordings, and LTP assays in IB2 knockout mouse cerebellar slices\",\n      \"pmids\": [\"30696733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between JIP2 scaffolding and NMDA receptor current changes not established\", \"Whether the phenotype is JNK-dependent untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified JIP2 as a translationally regulated effector downstream of HPV E6, answering how E6 engages noncanonical WNT/JNK signaling to drive proliferation.\",\n      \"evidence\": \"Polysome profiling, RNAseq, siRNA silencing, ectopic rescue, in vitro and in vivo tumor growth assays\",\n      \"pmids\": [\"31637011\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of selective JIP2 mRNA translation by E6 not defined\", \"Direct scaffolding role of JIP2 in WNT/PCP/JNK output not biochemically dissected\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Embedded JIP2 in a cardioprotective signaling axis, showing it physically associates with CTRP3 and LAMP1 to modulate JNK during I/R injury.\",\n      \"evidence\": \"Co-immunoprecipitation, siRNA knockdown, overexpression, JNK inhibitor treatment, in vivo mouse I/R model\",\n      \"pmids\": [\"35278832\", \"35114641\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-IP without reciprocal or structural validation of the JIP2–LAMP1 interaction\", \"Direct vs indirect nature of CTRP3–JIP2 contact unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided the structural and functional basis for JIP2 dimerization, resolving how SH3-mediated homo- and heterodimers control JNK pathway activation.\",\n      \"evidence\": \"NMR, X-ray crystallography of the JIP2-SH3 homodimer, site-directed mutagenesis, cell-based JNK activation assays\",\n      \"pmids\": [\"39013462\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and architecture of full-length JIP1/JIP2 scaffolds with kinases not resolved\", \"How dimerization couples to specific JNK substrate selection unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How JIP2 scaffolding switches between cytosolic JNK retention and active JNK pathway assembly across cell types remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking SH3 dimerization state to JNK localization\", \"Full set of kinase partners assembled on the JIP2 scaffold not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 4, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MAPK8IP1\", \"LAMP1\", \"CTRP3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":4,"faith_total":5,"faith_pct":80.0}}